News 2020-07-03
The Launching of Official Website for 2020 Pharmaceutical Crystallization Summit
J-Star Research, a wholly owned subsidiary of Porton Pharma Solution Ltd., engages with Xtalpi and a broad selection of industrial and academic leaders to host the 2020 Pharmaceutical Crystallization Summit on October 7th and 8th, 2020 (Live).
We will take a close look at the ever-expanding toolbox of capabilities needed to meet challenges in API crystallization. The Summit will emphasize the importance of understanding fundamentals and root causes of problems to effectively speed up process and product development.
Considering the impact of the Covid-19 outbreak, this year’s Summit will be held online (live). This provides the advantage of allowing more attendees than a normal face-to-face meeting. The registration for invited attendees starts in June, and the registration for the general public starts on August 7th, 2020. Registration Reminder for public audience will be released through Porton official channels in August.
Warmly welcome our customers and investors to follow us on this Summit in the coming months.
Website:
https://crystallization-summit.jstar-research.com/
LinkedIn:
https://www.linkedin.com/company/center-for-pharma-crystallization-cfpc/
Others
MoreNews 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.